<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02122731</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2009-017033</org_study_id>
    <nct_id>NCT02122731</nct_id>
  </id_info>
  <brief_title>Amiloride for Resistant Hypertension</brief_title>
  <official_title>Southern Danish Hypertension and Diabetes Study (SDHDS) With Amiloride</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ib Abildgaard Jacobsen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the antihypertensive effect of amiloride added to triple antihypertensive therapy
      in patients with resistant hypertension (RH) and type 2 diabetes mellitus (T2DM)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study was to evaluate the antihypertensive effect of amiloride
      added to triple antihypertensive treatment in patients with resistant hypertension and type 2
      diabetes mellitus in an open-labelled, non- controlled and non-randomized interventional
      study.

      The secondary objectives were to evaluate the additional effects of amiloride on:

        -  Urinary albumin excretion

        -  Blood pressure control, how many patients reached blood pressure control when amiloride
           was added to previous triple antihypertensive treatment.

        -  Plasminogen and plasmin excretion (ENaC activity) in the micro-and macroalbuminuric
           patients in the cohort.

        -  Urokinase plasminogen activator (uPA) activity
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>average daytime systolic and diastolic blood pressure</measure>
    <time_frame>8 weeks</time_frame>
    <description>ambulatory blood pressure monitoring was performed at baseline and after 8 weeks intervention with amiloride</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary albumin excretion</measure>
    <time_frame>after 8 weeks</time_frame>
    <description>Urine albumin was measured at baseline and after 8 weeks of amiloride treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma potassium</measure>
    <time_frame>after 4 and 8 weeks</time_frame>
    <description>plasma potassium tend to increase during amiloride treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary urokinase plasminogen activator (uPA) activity</measure>
    <time_frame>At baseline and after 8 weeks of amiloride treatment</time_frame>
    <description>uPA exist in urine where it cleaves plasminogen to plasmin. uPA is possible secreted fra the tubulus cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine plasminogen and plasmin</measure>
    <time_frame>at baseline and after 8 weeks of amiloride treatment</time_frame>
    <description>U-plasminogen is filtered to urine in patients with microalbuminuria. In urine plasminogen is activated to plasmin by urokinase plasminogen activator.Plasmin activates the epithelial sodium channel.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Hypertension</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Microalbuminuria</condition>
  <arm_group>
    <arm_group_label>Amiloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a non-randomized and non-controlled study with only one treatment arm with amiloride.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiloride</intervention_name>
    <description>5 mg(daily of amiloride was added to patients triple antihypertensive therapy and increased to 10 mg/daily if office blood pressure at 4 weeks was above 130/80 mmHg.</description>
    <arm_group_label>Amiloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed with resistant hypertension (average daytime BP &gt;130and/or &gt;80 mmHg by
             ambulatory monitoring in spite of treatment with 3 antihypertensive drugs including a
             diuretic and an angiotensin coverting enzyme inhibitor (AECi) or angiotensin recpetor
             blocker (ARBs) and a third optional, all in optimal dosages.

          -  type 2 diabetes

          -  prior participant in a randomized controlled trial with spironolactone, but after a
             wash-out periods of minimum two weeks (NCT01062763)

        Exclusion Criteria:

          -  Office blood pressure (BP) &gt;180/110 mmHg

          -  daytime average BP by ambulatory monitoring &gt; 170/85 mmHg

          -  heart failure (NYHA III-IV) Cardiac arrythmia HbA1C &gt; 10% severe dyslipidemia known or
             with signs of secondary hypertension estimated glomerular filtration rate (eGFR)
             &lt;50ml/min per 1.73 m2 prior intolerance to spironolactone or amiloride fertility
             without oral contraception pregnancy lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ib A Jacobsen, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of endocrinology, Odense University Hospital, Odense, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sydvestjysk Hospital, Esbjerg</name>
      <address>
        <city>Esbjerg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sygehus Lillebaelt.</name>
      <address>
        <city>Fredericia</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steno Diabetes Center</name>
      <address>
        <city>Gentofte</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital, Department of Endocrinology</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Oxlund CS, Henriksen JE, Tarnow L, Schousboe K, Gram J, Jacobsen IA. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens. 2013 Oct;31(10):2094-102. doi: 10.1097/HJH.0b013e3283638b1a.</citation>
    <PMID>24107738</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2014</study_first_submitted>
  <study_first_submitted_qc>April 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2014</study_first_posted>
  <last_update_submitted>April 23, 2014</last_update_submitted>
  <last_update_submitted_qc>April 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Ib Abildgaard Jacobsen</investigator_full_name>
    <investigator_title>Consultant Physician</investigator_title>
  </responsible_party>
  <keyword>antihypertensive therapy</keyword>
  <keyword>amiloride</keyword>
  <keyword>add-on</keyword>
  <keyword>resistant hypertension</keyword>
  <keyword>blood pressure control</keyword>
  <keyword>type 2 diabetes mellitus,</keyword>
  <keyword>microalbuminuria.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

